Latest Regulatory News

GreenTech Metals has responded to an ASX price query following a sharp rise in its share price, confirming no undisclosed information beyond prior announcements. The company highlights its recent acquisition and a strong market for platinum group elements as context.

NEXTDC has received State Significant Development approval for its S4 Sydney Data Centre at Horsley Park, clearing a major regulatory hurdle for its expansion plans in New South Wales.

The Supreme Court of New South Wales has approved the acquisition of Seven West Media by Southern Cross Media, marking a major consolidation in Australian media. SWM shares will be suspended from trading as shareholders prepare to receive Southern Cross shares in early January.

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Clarity Pharmaceuticals’ novel diagnostic agent Cu-SAR-bisPSMA has been selected for oral presentation at the prestigious European Association of Urology Congress 2026, following promising Phase II trial results demonstrating superior detection of prostate cancer recurrence.

JAYRIDE Group has amended its quarterly cash flow report to correct classification errors, while outlining plans for a new SaaS platform rollout and potential capital raising to support operations.

Native Mineral Resources Holdings has locked in a $3 million convertible note raising from Lind Global Fund III LP, with the option to access up to $10 million. The funding aims to bolster working capital and support growth in the Charters Tower region.

Dart Mining NL reports encouraging 2024 diamond drilling results at its Rushworth project in Victoria, revealing multiple wide gold mineralised lodes at the Phoenix Reef prospect. The company plans to resume drilling in 2026, targeting new structural zones identified by recent interpretations.

Antilles Gold has received an interim distribution of A$3.25 million from the liquidation of a former subsidiary, directing these funds to support construction of its Nueva Sabana copper-gold mine in Cuba.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

Beacon Minerals has agreed to sell its Mt Dimer tenements to Forrestania Resources for A$50,000, marking a strategic move to focus on core assets and reduce costs.

Forrestania Resources has acquired key tenements at Mt Dimer from Beacon Minerals, significantly expanding its gold exploration footprint in Western Australia’s Southern Cross Domain. The move aligns with the company’s strategy to consolidate and explore highly prospective gold belts.